NNNaoki Nishio

Naoki Nishio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Naoki Nishio has a total of 334 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tailoring Surgical Strategy for Advanced Lateral Skull Base Malignancies: Anatomical Constraints and Histological Limits in Margin Control

    by Kenichiro Iwami, Shoichi Deguchi, Naoki Nishio, Seiya Goto, Takashi Maruo, Kazuhito Takeuchi, Yuichi Nagata, Tomoki Matsuyama, Eriko Okumura, Fumiharu Ohka, et al.

  • Open Access

    Darolutamide Alone and in Combination With Goserelin in Androgen Receptor–Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial

    by Susumu Okano, Makoto Tahara, Kiyoaki Tsukahara, Tomoyuki Otsuka, Satoshi Kano, Masato Nagaoka, Hideoki Uryu, Daisuke Sano, Naoki Nishio, Kazuchika Ono, et al.

    PURPOSE: Salivary gland carcinoma (SGC), particularly salivary duct carcinoma (SDC), is a rare and aggressive malignancy with no standard systemic treatment. Androgen receptor (AR) expression is frequently detected in SDC, which suggests inhibition of the AR pathway as a therapeutic strategy. We conducted a prospective phase II trial of the efficacy and safety of darolutamide, a second-generation AR signaling inhibitor, as monotherapy or in combination with goserelin, in patients with AR-positive unresectable locally advanced (LA) or recurrent/metastatic (R/M) SGC. METHODS: DISCOVARY was a multicenter, single-arm, phase II trial conducted in Japan. Patients with unresectable LA or R/M AR-positive SGC were enrolled into two sequential cohorts, a monotherapy cohort (darolutamide 600 mg orally twice daily) and a combination cohort (darolutamide plus goserelin 3.6 mg subcutaneously once every 28 days). The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), safety, and health-related quality of life. RESULTS: Fifty-seven patients were enrolled (monotherapy, n = 24; combination, n = 33). In the monotherapy cohort, the confirmed ORR was 8.3% (90% CI, 1.5 to 24.0) and the median PFS was 5.7 months. In the combination cohort, ORR was 45.2% (90% CI, 29.7 to 61.3) and the median PFS was 13.1 months. Twelve-month OS rates were 91.3% and 87.0%, respectively. Most adverse events were grade 1 or 2 in severity, with no treatment-related deaths. Quality of life was preserved. No clear association between AR expression level or Ki-67 index and treatment response was evident in exploratory analysis. CONCLUSION: Darolutamide demonstrated antitumor activity in AR-positive SGC, with numerically more favorable outcomes with goserelin. Darolutamide plus goserelin may represent a chemotherapy-sparing option in this rare malignancy.

  • Open Access

    A multicenter randomized phase III trial to evaluate the value of omission of elective neck dissection for T3–T4aN0 laryngeal cancer: JCOG2407 (JALNECK)

    by Kota Kawabata, Yuki Saito, Akihiro Homma, Nobuhiro Hanai, Naoki Nishio, Yoshitaka Honma, Yosuke Ariizumi, Kaori Hashimoto, Shintaro Beppu, Takashi Mukaigawa, et al.

    Total laryngectomy with paratracheal dissection and elective lateral neck dissection (ELND) is the standard surgical procedure for T3–T4aN0 laryngeal cancer. However, ELND is associated with increased surgical invasiveness, higher risk of postoperative complications, and long-term functional impairment. Although previous studies suggest that ELND omission may reduce postoperative complications, including pharyngocutaneous fistulas and deterioration in quality of life (QOL), its impact on prognosis remains controversial. Therefore, we designed a multicenter, randomized phase III trial (JCOG2407) to confirm the non-inferiority of total laryngectomy with paratracheal dissection alone compared to surgery including ELND for T3–T4aN0 laryngeal cancer. The primary endpoint is overall survival. The secondary endpoints include short-term outcomes, postoperative complications, functional assessments, and QOL. A total of 280 patients from 39 institutions will be enrolled over 5 years. This trial has been registered with the Japan Registry of Clinical Trials (study number: jRCT1030250729).

  • Open Access

    The laryngofissure approach for near-infrared photoimmunotherapy in laryngeal cancer: A novel larynx-preservation strategy

    by Naoki Nishio, Mayu Shigeyama, Akihisa Wada, Seiya Goto, Sayaka Yokoi, Michihiko Sone

  • Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer

    by Makoto Tahara, Naomi Kiyota, Takeshi Kodaira, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Yuji Hirayama, Yusuke Onozawa, Naoki Nishio, Nobuhiro Hanai, et al.

    The interim analysis of JCOG1008 demonstrated that chemoradiotherapy with cisplatin 40 mg/m 2 once a week for seven cycles (weekly cisplatin) was noninferior in terms of overall survival (OS) compared with chemoradiotherapy with cisplatin 100 mg/m 2 once every 3 weeks for three cycles (3-weekly cisplatin) for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). This report presents the long-term follow-up results of JCOG1008. In this phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin or with weekly cisplatin. A total of 261 patients were enrolled. At the final analysis, with a median follow-up of 5.6 years, 5-year OS was 58.7% in the 3-weekly arm and 71.2% in the weekly arm (hazard ratio, 0.76 [95% CI, 0.52 to 1.12 [<1.32]]), confirming the noninferiority of the weekly regimen. Both 5-year relapse-free survival (RFS) and 5-year local RFS were numerically better in the weekly arm. No late adverse event showed more than a 10% difference between the two arms. In conclusion, 5-year follow-up confirmed that chemoradiotherapy with weekly cisplatin is noninferior in OS to chemoradiotherapy with 3-weekly cisplatin in patients with postoperative high-risk LA-SCCHN. These results further support the use of weekly cisplatin plus radiotherapy as a reasonable alternative for this patient population.


  • Open Access

    Successful management of near-infrared photoimmunotherapy-induced skin injury using pedicled flap transfer

    by Mayu Shigeyama, Naoki Nishio, Akihisa Wada, Seiya Goto, Sayaka Yokoi, Michihiko Sone

  • Open Access

    Transoral videolaryngoscopic surgery for hypopharyngeal anaplastic metastasis from papillary thyroid carcinoma

    by Yuya Yokoyama, Naoki Nishio, Mai Sugiura, Katsunao Suzuki, Akihisa Wada, Michihiko Sone

    We report an extremely rare case of hypopharyngeal metastasis with anaplastic transformation (anaplastic thyroid carcinoma) originating from papillary thyroid carcinoma, demonstrating successful tumor control using minimally invasive transoral surgery combined with targeted therapy. A 78-year-old man with a history of papillary thyroid carcinoma treated with total thyroidectomy and radioactive iodine 10 years earlier presented with sore throat and difficulty swallowing. Fiberoptic examination revealed a 25-mm mass on the posterior hypopharyngeal wall causing airway compromise, necessitating an emergency tracheotomy. Biopsy confirmed hypopharyngeal metastasis with anaplastic thyroid carcinoma. Given his comorbidities (chronic leukemia, severe pulmonary arterial hypertension), he underwent transoral videolaryngoscopic surgery to achieve local tumor control while preserving swallowing function. Postoperative genetic testing detected a BRAF V600E pathogenic variant, leading to treatment with encorafenib and binimetinib, initiated on postoperative day 24. Six months after surgery and targeted therapy, fiberoptic examination and contrast-enhanced computed tomography showed no evidence of recurrent disease; the tracheostomy was closed, and the patient maintained normal swallowing and quality of life. This case illustrates that a surgery-first, function-preserving approach integrated with early molecular-targeted BRAF/MEK inhibition can achieve durable local control and maintain laryngopharyngeal function, even when anaplastic transformation occurs within a hypopharyngeal metastatic focus.

  • Open Access

    A Voice Conversion System from Electrolarynx Speech to Preoperative Patient's Speech for Total Laryngectomy

    by Naoki Nishio, Kazuhiro Kobayashi, Ding Ma, Sohei Mitani, Michihiko Sone, Tomoki Toda

    Laryngectomy is a life‐changing procedure typically performed as a surgical treatment for patients with head and neck cancer. Voice conversion (VC) is a technology that converts one voice into another without changing the linguistic information. Recently, “Save the Voice Project” for patients planning to undergo laryngectomy using our VC technique has been initiated. This study evaluated the speech converted from EL speech using the VC technique in a patient with head and neck cancer who had undergone laryngectomy. Additionally, details of an iPhone/iPad application for voice recording were reported. VC technology would greatly improve the quality of life of patients planning to undergo laryngectomy, especially those with relatively well‐preserved vocal function. To preserve the patient's original normal speech, medical staff should perform voice management before and after laryngectomy, and high‐quality voice recordings are essential.


  • Open Access

    Development and validation of an electrosurgery-compatible simulation task for quantitatively assessing oral cancer resection skills

    by Kayo Sakamoto, Sohei Mitani, Naoki Nishio, Takashi Kitani, Eriko Sato, Keiko Tanaka, Toru Ugumori, Hiroyuki Wakisaka, Naohito Hato

    Background The quality of oral cancer resection is extremely important for patient outcomes, such as local control and survival. However, most current simulators either provide only subjective feedback or are not compatible with electrosurgery. Therefore, we developed an electrosurgical simulation task for oral cancer resection that provides quantitative metrics and investigated its validity. Methods We developed a soft tissue simulation task using a plant-derived model that supports electrosurgery. As quantitative measures demonstrating “ensuring appropriate margins” in oral cancer resection and “maintaining safety” during electrosurgery, we employed nine-directional margin error distance and tumor bed carbonization degree measured using a spectral colorimeter. As validity evidence of the task, 10 expert surgeons completed a questionnaire about the task. In addition, five experts and 12 novices performed the task, and quantitative data obtained from their performance was used for evaluation. Results The replication of oral cancer resection was highly evaluated (4.4 out of 5 points), and quantitative measures for evaluating the skills of surgeons (4.8 out of 5 points) were agreed upon by experts. The internal consistency of the measures was good (Cronbach's alpha: 0.803). Compared to novices, experts had smaller margin errors (0.79 mm vs 2.45 mm), lower carbonization (ΔE: 2.33 vs 8.70), faster resection times, and fewer grasping attempts (all P < 0.0001). Conclusion This user-friendly plant-derived simulation task is compatible with electrosurgery and can quantitatively assess proficiency in oral cancer resection. Using this task is expected to promote early acquisition of tumor resection skills and improve oncological safety.

  • Open Access

    Retrospective study of definitive therapy for head and neck mucosal melanoma: The RESUME study

    by Motoo Nomura, Naomi Kiyota, Yasushi Shimizu, Atsushi Motegi, Tetsuo Akimoto, Takashi Mukaigawa, Takashi Fujii, Nayuta Tsushima, Kiyoto Shiga, Taiji Koyama, et al.